These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 24104359)

  • 1. FDA advisory panel recommends approval of drug for preoperative treatment of breast cancer.
    Jin J
    JAMA; 2013 Oct; 310(14):1434. PubMed ID: 24104359
    [No Abstract]   [Full Text] [Related]  

  • 2. Pertuzumab (Perjeta) for preoperative use in HER2-positive breast cancer.
    Med Lett Drugs Ther; 2013 Dec; 55(1431):98-9. PubMed ID: 24322664
    [No Abstract]   [Full Text] [Related]  

  • 3. Is the Preoperative Setting an Appropriate Platform for Drug Approval in Breast Cancer?
    Kaklamani VG; Gradishar WJ
    J Natl Compr Canc Netw; 2015 Nov; 13(11):1448-52. PubMed ID: 26553770
    [No Abstract]   [Full Text] [Related]  

  • 4. Pertuzumab and its accelerated approval: evolving treatment paradigms and new challenges in the management of HER2-positive breast cancer.
    O'Sullivan CC; Connolly RM
    Oncology (Williston Park); 2014 Mar; 28(3):186-94, 196. PubMed ID: 24855725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant trials could speed up drug approvals.
    Peres J
    J Natl Cancer Inst; 2014 Mar; 106(3):dju072. PubMed ID: 24610911
    [No Abstract]   [Full Text] [Related]  

  • 6. Pertuzumab (Perjecta) for HER2-positive metastatic breast cancer.
    Med Lett Drugs Ther; 2012 Jul; 54(1395):59-60. PubMed ID: 22825690
    [No Abstract]   [Full Text] [Related]  

  • 7. FDA cancels approval for bevacizumab in advanced breast cancer.
    Tanne JH
    BMJ; 2011 Nov; 343():d7684. PubMed ID: 22121166
    [No Abstract]   [Full Text] [Related]  

  • 8. FDA panel votes to pull Avastin in breast cancer, again.
    Ratner M
    Nat Biotechnol; 2011 Aug; 29(8):676. PubMed ID: 21822226
    [No Abstract]   [Full Text] [Related]  

  • 9. FDA approves pertuzumab for breast cancer.
    Traynor K
    Am J Health Syst Pharm; 2012 Jul; 69(14):1178. PubMed ID: 22761063
    [No Abstract]   [Full Text] [Related]  

  • 10. Neoadjuvant pertuzumab: the exception that proves the rule?
    Burstein HJ
    Oncology (Williston Park); 2014 Mar; 28(3):197-9. PubMed ID: 24855726
    [No Abstract]   [Full Text] [Related]  

  • 11. Pertuzumab: increasing the options.
    Nunes R; Swain SM
    Oncology (Williston Park); 2014 Mar; 28(3):199, 204, 210. PubMed ID: 24855727
    [No Abstract]   [Full Text] [Related]  

  • 12. First FDA approval of neoadjuvant therapy for breast cancer: pertuzumab for the treatment of patients with HER2-positive breast cancer.
    Amiri-Kordestani L; Wedam S; Zhang L; Tang S; Tilley A; Ibrahim A; Justice R; Pazdur R; Cortazar P
    Clin Cancer Res; 2014 Nov; 20(21):5359-64. PubMed ID: 25204553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Avastin saga reveals debate over clinical trial endpoints.
    Sharma SP
    J Natl Cancer Inst; 2012 Jun; 104(11):800-1. PubMed ID: 22673590
    [No Abstract]   [Full Text] [Related]  

  • 14. Neoadjuvant trastuzumab for breast cancer. Better to stick with proven treatments.
    Prescrire Int; 2013 Feb; 22(135):39. PubMed ID: 23444499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pushing the envelope.
    Nat Biotechnol; 2011 Aug; 29(8):669. PubMed ID: 21822220
    [No Abstract]   [Full Text] [Related]  

  • 16. FDA pulls approval for avastin in breast cancer.
    Rose S
    Cancer Discov; 2011 Dec; 1(7):OF1-2. PubMed ID: 22586694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [New approaches to the treatment of breast cancer].
    Semiglazov VF
    Vopr Onkol; 2013; 59(3):288-91. PubMed ID: 23909027
    [No Abstract]   [Full Text] [Related]  

  • 18. Oncologic drugs advisory committee recommends withdrawing approval for bevacizumab use in breast cancer treatment.
    Future Oncol; 2010 Sep; 6(9):1374. PubMed ID: 20931736
    [No Abstract]   [Full Text] [Related]  

  • 19. Changing end points in breast-cancer drug approval--the Avastin story.
    D'Agostino RB
    N Engl J Med; 2011 Jul; 365(2):e2. PubMed ID: 21707384
    [No Abstract]   [Full Text] [Related]  

  • 20. Pharmacogenomics at work.
    Nat Biotechnol; 1998 Oct; 16(10):885. PubMed ID: 9788323
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.